Lana Pine

Cannabidiol (CBD) may be used separately or in conjunction with standard treatment to reduce symptoms of juvenile idiopathic arthritis.

“Although many different autoantibodies have been investigated in SLE, only a limited number of autoantibodies are being used in clinical practice,” investigators stated. “Due to these limitations, there has been great interest in the discovery of new autoantibodies that can be used in clinical practice.”

The US FDA approved upadacitinib (15 mg daily) for the treatment of adults with active psoriatic arthritis with inadequate response to at least 1 TNF blocker.

Test your knowledge of the treatment and management of rheumatoid arthritis with our latest RA quizzes.

"Understanding the effects of the pandemic on specific areas of health care is crucial for future planning in both the immediate and longer term," stated investigators.

Smoking increased the risk of developing malar rash and mucosal ulcers as well as increasing the likelihood of experiencing migraine, Raynaud’s phenomenon, and arthritis symptoms.

Women with systemic lupus erythematosus are more likely to have accelerated progression of atherosclerosis. Recognizing the risk factors, such as larger waist circumference and higher fasting glucose levels, may be an important step in preventing this condition.

“Preliminary evidence has suggested that an exercise training could be effective in improving physical function and quality of life in juvenile dermatomyositis, without exacerbating the disease,” investigators stated.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 10, 2021.

Investigators theorized that this questionnaire, in conjunction with autoantibody determination, could help screen for SLE in the early stages of the disease.

James Woody, MD, PhD, explains the key findings of the Phase 2b clinical trial, “Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD).”

Jessica Walsh, MD, explains the importance of understanding treatment satisfaction and decision-making in patients with axial spondyloarthritis based on patient-reported outcomes.

Roy Fleischmann, MD, explores the successful results of the novel IL-6 inhibitor, olokizumab, from 2 randomized clinical trials of the phase 3 global research program CREDO.

Crohn’s disease inflames the gastrointestinal tract and causes consistent abdominal pain and diarrhea. Upadacitinib (AbbVie), a reversible Janus kinase (JAK) inhibitor, may be able to help patients achieve clinical remission.

Selective Janus kinase (JAK) inhibitor, upadacitinib, is now intended for adults with moderate-to-severe rheumatoid arthritis (RA) who have had inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker.

On this month's episode of Overdrive, Rheumatology Network interviewed Courtney Wells, PhD, MPH, MSW, to discuss the impact of COVID-19 on the quality of life of patients with rheumatic conditions, focusing on perceived risk and decision making.

Previous studies examining whether inflammatory disease was associated with an increased risk of Alzheimer's disease yielded mixed results.

Andrew Concoff, MD, explores the benefits of a gel that significantly improves clinical outcomes for patients with rheumatoid arthritis and decreases the need for concomitant medications.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 3, 2021.

Stuart Kassan, MD, discusses Rheumatology Research Foundation's recent patient webinar, "Just Diagnosed: Now What?”

Philip Mease, MD, explains the recent Phase 3 data from the DISCOVER-1 and DISCOVER-2 clinical trials which demonstrated guselkumab inhibited radiographic progression, and improved symptoms and pain in patients with active psoriatic arthritis (PsA).

Louis Bessette, MD, MSc, explains the impact of early pain improvement on patient-reported outcomes in patients with psoriatic arthritis.

Benjamin Terrier, MD, PhD, discusses his study and ACR presentation, “Rituximab versus Conventional Therapeutic Strategy for Remission Induction in Eosinophilic Granulomatosis with Polyangiitis: A Double-blind, Randomized, Controlled Trial.”

Paul R. Fortin, MD, MPH, FRCPC, discusses the impact of the COVID-19 vaccine in immunosuppressed adults and those with autoimmune diseases.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending November 26, 2021.

Ana-Maria Orbai, MD, FACR, MHS, explains how guselkumab improved PROMIS-29 scores in patients with psoriatic arthritis.

Soumya Chakravarty, MD, PhD, discusses the unmet patient needs in immune-mediated diseases and Janssen’s role in scientific innovation that allows patients to live their lives unburdened by disease.

Mithu Maheswaranathan, MD, discusses the association of health literacy in terms of both clinical and self-reported outcomes for patients with systemic lupus erythematosus.

Robert Terkeltaub, MD, explains the results from a phase 2, dose-finding study to determine the safety and efficacy of tigulixostat in patients with gout.

Courtney Wells, PhD, MPH, MSW, discusses the impact of the pandemic on the quality of life of patients with rheumatic conditions, with an emphasis on perceived risk and decision making.